Brief: Eton Pharmaceuticals Announces Acquisition Of U.S. Rights To Amglidia
25/11/2024 14:03
Nov 25 (Reuters) - Eton Pharmaceuticals Inc ETON.O :
* ETON PHARMACEUTICALS ANNOUNCES ACQUISITION OF U.S. RIGHTS
TO
AMGLIDIA (GLYBURIDE ORAL SUSPENSION)
* ETON PHARMACEUTICALS INC - PLANS FDA MEETING IN Q1 2025,
NDA
SUBMISSION IN 2026
Source text: ID:nGNX1q6PZ3
Further company coverage: ETON.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Eton Pharmaceuticals
See all newsBrief: Eton Pharmaceuticals Under Agreement, Co Pays Aquestive Upfront License Fee Of $10 Million - SEC Filing
Aquestive rises on US licensing deal for seizure drug with Eton Pharma
U.S. STOCKS ON THE MOVE-Sun Communities, Cisco Systems, Paysafe
U.S. STOCKS ON THE MOVE-Fox, Sun Communities, Reddit, drone firms
U.S. STOCKS ON THE MOVE-Boost Run, Nektar Therapeutics, Swarmer